

Supplemental Figure 1. Titration of AMPKα1 siRNA and AMPKα2 siRNA based on AMPKα and PGC-1α expression in myotubes. (A) Pictures of L6 myotubes treated with Lipofectamine (control vehicle) or transfected with fluorophore-conjugated siRNA (siGLO® green) for 24 hours (Merged pictures are shown, Blue - depicts nuclei stained with DAPI, Green - depicts siRNA, magnification =200x), (B) Effect of either AMPKα1 siRNA or AMPKα2 siRNA on AMPKα1 mRNA expression (n=4/group, \*P<0.05 in comparison to Control [open bar], #P<0.05 in comparison to other concentrations of AMPKα2 siRNA), (C) Effect of either AMPKα1 siRNA or AMPKα2 siRNA on AMPKα2 mRNA expression (n=3-

4/group, \*P<0.05 in comparison to Control [open bar], # P<0.05 in comparison to other concentrations of AMPKα1 siRNA), (D) Effect of different concentrations of AMPKα1 siRNA and AMPKα2 siRNA used in combination on AMPKα1 mRNA and AMPKα2 mRNA expression (n=4/group, \*P<0.05 in comparison to Control and Lipofectamine), (E) Effect of AMPKα1 siRNA and AMPKα2 siRNA used in combination on AMPKα protein expression at different time points after transfection (n=3/group,\*P<0.05 in comparison to Control), (F) Effect of AMPKα1 siRNA and AMPKα2 siRNA used alone or in combination on PGC-1α mRNA expression (n=3-4/group). Samples were harvested 48 hours after transfection in all experiments, except for A as described above.